Clinical Trials Logo

Filter by:
NCT ID: NCT04607486 Completed - Clinical trials for Cerebrovascular Accident

Investigation of Changes in Lower Limb Muscles After Cerebrovascular Accident

Start date: June 18, 2018
Phase:
Study type: Observational [Patient Registry]

The aim of this study is to investigate lower limb muscles after cerebrovascular accident

NCT ID: NCT04604769 Completed - Coronavirus Clinical Trials

Perceived Stress Among ICU Medical Staff During COVID-19 Crisis

ICUcovid
Start date: June 26, 2019
Phase:
Study type: Observational

The objective of this study is to compare psychological distress and needs of nurses in ICU before and during coronavirus pandemic.

NCT ID: NCT04602780 Completed - Hearing Loss Clinical Trials

Evaluating the Revised WORQ in CI Users

Start date: September 4, 2019
Phase:
Study type: Observational

The Work Related Questionnaire (WORQ) is a 59-item questionnaire of which each item represents an International Classification of Functioning and disability category. The WORQ was modified and reduced to include only questions relevant to Cochlear Implant (CI) users. In this analysis, a multicentre retrospective review of the revised WORQ in CI users was performed, with the revised WORQ as part of the questionnaires used in the regular clinical follow-up of CI users. Experienced CI users' responses on the questions will be evaluated to define the qualifiers for the revised WORQ.

NCT ID: NCT04601844 Completed - Healthy Clinical Trials

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Pozelimab in Combination With Cemdisiran in Healthy Adult Volunteers

Start date: November 16, 2020
Phase: Phase 1
Study type: Interventional

The primary objective of the study is to evaluate the safety and tolerability of ascending doses of subcutaneous (SC) pozelimab and SC cemdisiran when administered on the same day or sequentially 28 days apart. The secondary objectives of the study are: - To assess the concentration-time profiles of total pozelimab, total complement component 5 (C5), cemdisiran, and cemdisiran metabolite(s) following single ascending doses of SC pozelimab and SC cemdisiran when administered on the same day or sequentially 28 days apart - To assess the pharmacodynamic (PD) profile of ascending doses of SC pozelimab and SC cemdisiran, as well as when administered on the same day or sequentially 28 days apart - To assess the immunogenicity of pozelimab and cemdisiran

NCT ID: NCT04600531 Completed - Healthy Clinical Trials

Conventional or High Definition tDCS to Enhance Implicit Motor Sequence Learning in Healthy Young Adults?

Start date: October 15, 2020
Phase: N/A
Study type: Interventional

Implicit motor sequence learning (IMSL) is a form of cognitive function that is known to be directly associated with motor function. This hallmark motor skill enables humans to perform multiple single movements in a specific sequential order and is involved in many of our daily activities (e.g. reaching, dressing, typing). One promising tool that has been shown to improve this type of learning in healthy young individuals, is transcranial direct current stimulation (tDCS). This non-invasive brain stimulation technique entails the administration of a weak electrical current at the scalp between two electrodes. To date, studies have almost exclusively investigated effects of conventional tDCS. Recently, however, novel High Definition (HD) tDCS devices have been commercialised. Whereas conventional tDCS uses two rather large electrodes, likely including adjacent cortical areas in the stimulation, HD-tDCS uses multiple smaller electrodes, allowing for stimulation of the targeted cortical region with higher resolution/specificity. The aim of the present study is to confirm previous findings suggesting beneficial effects of conventional tDCS, delivered over the primary motor cortex (M1) in healthy young adults. Additionally, the investigators will be the first to investigate potential effects of HD tDCS on IMSL in this population and to make a comparison between these two devices. The investigators will determine immediate effects that may occur concurrently with the application of tDCS but also short-term (five minutes post-tDCS) and long-term (one week post-tDCS) consolidation effects, as previous studies suggest that tDCS exerts its beneficial effects on IMSL in a consolidation phase rather than in an acquisition phase.

NCT ID: NCT04599465 Completed - Cystic Fibrosis Clinical Trials

A Study to Assess the Effect of ELX/TEZ/IVA on Glucose Tolerance in Participants With Cystic Fibrosis (CF)

Start date: January 15, 2021
Phase: Phase 3
Study type: Interventional

This study was evaluate the effect of elexacaftor (ELX)/tezacaftor (TEZ)/ivacaftor (IVA) on glucose tolerance in CF participants, 12 years of age and older who are heterozygous for the F508del mutation and a minimal function mutation (F/MF genotypes), with abnormal glucose metabolism.

NCT ID: NCT04597632 Completed - Clinical trials for Neovascular Age-related Macular Degeneration

An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study

TALON Ext
Start date: December 16, 2020
Phase: Phase 3
Study type: Interventional

The purpose of this extension study was to evaluate the efficacy and safety of brolucizumab used in a Treat-to-Control-regimen for treatment of patients with neovascular age-related macular degeneration who have completed the CRTH258A2303 (TALON) study. The main objective was to assess brolucizumab's potential for long durability up to 20 weeks. All eligible participants were treated with brolucizumab regardless of their treatment in the TALON study. The study period was 56 weeks including post-treatment follow-up.

NCT ID: NCT04595370 Completed - Heart Failure Clinical Trials

Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney Disease

MIRACLE
Start date: January 26, 2021
Phase: Phase 2
Study type: Interventional

The purpose of the study is to evaluate the efficacy and safety of AZD9977 in combination with dapagliflozin compared with dapagliflozin alone and to assess the dose-response relationship, dapagliflozin alone and 3 doses of AZD9977 combined with dapagliflozin on urinary albumin to creatinine ratio (UACR). The study will be conducted in participants with heart failure (HF) with left ventricular ejection fraction (LVEF [below 60%]) and chronic kidney disease (CKD) with estimated glomerular filtration rate (eGFR [between ≥ 20 and ≤ 60 mL/min/1.73 m^2, with at least 20% of participants with eGFR ≥ 20 to <30 mL/min/1.73^2 and a maximum of 35% of participants with eGFR ≥ 45 mL/min/1.73 m^2]).

NCT ID: NCT04594148 Completed - Healthy Aging Clinical Trials

The Effect of Training on Brain Activity During Postural Tasks in Older Adults

Start date: February 8, 2021
Phase: N/A
Study type: Interventional

Older people show deficits in dynamic weight-shifting, as the investigators found that more time is needed to perform weight-shifts and the movements became less fluent and accurate in older versus younger adults. Deficits with weight-shifting in the mediolateral (left-right) direction have been linked to balance and falls in ageing. Balance control can be improved with training. Virtual reality (VR) based training programs for improving balance are gaining ground, as it can provide both fun and challenging balance tasks, enhancing motivation. The investigators demonstrated earlier that older adults show an overloaded neural activation pattern compared to young adults when performing the same VR-based mediolateral weight-shifting task (wasp game). What is yet unclear, is whether improved balance capacity can be gained with training and whether such an intervention impacts the underlying neural mechanisms. Using a combination of behavioral assessments and functional Near-Infrared Spectrocopy (fNIRS), the primary aim of this study is to investigate the effects of a VR-based weight-shift training and its underlying neural imprint in older adults. Furthermore, as a previous study done by the investigators also showed that adding an extra cognitive task in a so-called dual-task (DT) negatively affects weight-shifting performance, a secondary aim will be to test whether weight-shift training will enhance performance during such DT conditions. The results of this study may contribute to the future design of technology-based rehabilitation programs.

NCT ID: NCT04593251 Completed - Celiac Disease Clinical Trials

Dose Escalation Study to Evaluate an Experimental New Treatment (CALY-002) in Healthy Subjects and Subjects With Celiac Disease and Eosinophilic Esophagitis

Start date: September 28, 2020
Phase: Phase 1
Study type: Interventional

This is a single and multiple ascending study to characterize the safety, PK, PD and clinical effect in healthy volunteers and participants with Celiac Disease and Eosinophilic Esophagitis.